STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 54 filers reported holding STOKE THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $104,528 | -57.6% | 26,530 | +14.5% | 0.00% | – |
| Q2 2023 | $246,265 | -74.2% | 23,167 | -79.8% | 0.00% | – |
| Q1 2023 | $954,000 | +433536.4% | 114,467 | +379.8% | 0.00% | – |
| Q4 2022 | $220 | -99.9% | 23,859 | +1.2% | 0.00% | – |
| Q3 2022 | $302,000 | +1.7% | 23,568 | +4.8% | 0.00% | – |
| Q2 2022 | $297,000 | -27.9% | 22,498 | +14.7% | 0.00% | – |
| Q1 2022 | $412,000 | +5.6% | 19,608 | +20.8% | 0.00% | – |
| Q4 2021 | $390,000 | +4.0% | 16,234 | +10.2% | 0.00% | – |
| Q3 2021 | $375,000 | -19.0% | 14,728 | +7.2% | 0.00% | – |
| Q2 2021 | $463,000 | +24.1% | 13,745 | +43.3% | 0.00% | – |
| Q1 2021 | $373,000 | 0.0% | 9,589 | +59.4% | 0.00% | – |
| Q4 2020 | $373,000 | +139.1% | 6,016 | +32.1% | 0.00% | – |
| Q3 2020 | $156,000 | +39.3% | 4,554 | -2.9% | 0.00% | – |
| Q2 2020 | $112,000 | -11.1% | 4,691 | -14.8% | 0.00% | – |
| Q1 2020 | $126,000 | +46.5% | 5,505 | +82.3% | 0.00% | – |
| Q4 2019 | $86,000 | +34.4% | 3,019 | +0.6% | 0.00% | – |
| Q3 2019 | $64,000 | – | 3,001 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 296,822 | $9,991,000 | 2.07% |
| RTW INVESTMENTS, LP | 3,644,248 | $122,665,000 | 1.85% |
| Cormorant Asset Management, LP | 1,278,276 | $43,027,000 | 1.46% |
| Redmile Group, LLC | 2,458,558 | $82,755,000 | 1.22% |
| SPHERA FUNDS MANAGEMENT LTD. | 233,135 | $7,847,000 | 0.53% |
| Birchview Capital, LP | 15,000 | $505,000 | 0.30% |
| Perceptive Advisors | 1,343,956 | $45,238,000 | 0.29% |
| GILDER GAGNON HOWE & CO LLC | 1,245,956 | $41,939,000 | 0.21% |
| Artal Group S.A. | 250,000 | $8,415,000 | 0.17% |
| Casdin Capital, LLC | 120,000 | $4,039,000 | 0.10% |